Business
Nemaura Medical Inc. Announces Uplisting to NASDAQ Capital Market on January 25, 2018
Nemaura Medical Inc. Announces Uplisting to NASDAQ Capital Market on January 25, 2018.
About this update from Nemaura Medical, Inc.
[{"type":"text","content":"\n \n Nemaura Medical Inc. (“Nemaura”) (OTCQB: NMRD), a medical technology \n company developing the wireless sugarBEAT® non-invasive continuous \n glucose monitoring system for adjunctive use by persons with diabetes, \n today announced that its shares of common stock were approved for \n listing on the NASDAQ Capital Market.\n \n \n Trading on the NASDAQ Capital Market is expected to commence on January \n 25, 2018 under its existing trading symbol, NMRD.\n \n \n Dr Faz Chowdhury, Chief Executive Officer, stated, “Our listing on \n NASDAQ is a major corporate milestone which builds upon the technical \n and clinical progress we have made over the past few years. The listing \n coincides with the successful completion of our European Clinical \n Program and will help broaden our shareholder base, improve liquidity, \n and provide increased visibility and greater exposure to the \n institutional investor community, ultimately contributing to increasing \n shareholder value.”\n \n \n Nemaura completed its European Clinical Trials in December 2017 for its \n lead product sugarBEAT®, and is in the process of obtaining CE approval \n for product launch in the United Kingdom followed by multiple \n territories in Europe and the Middle East.\n \n \n Nemaura has signed non-binding heads of terms with major organizations \n in Europe, Gulf Co-operation Council, and Australia, for which full \n commercial agreements are expected to be completed in the coming weeks. \n Additionally, Nemaura is in discussions with multiple groups for \n licensing and marketing rights in other key territories.\n \n \n About Nemaura Medical, Inc.\n \n \n Nemaura Medical Inc. (OTCQB: NMRD), is a medical technology company \n developing sugarBEAT® as a non-invasive, affordable and flexible glucose \n monitoring system for adjunctive use by persons with diabetes. \n SugarBEAT® consists of a disposable adhesive skin-patch connected to a \n rechargeable transmitter, with an app displaying glucose readings. For \n more information, please visit www.NemauraMedical.com and www.SugarBEAT.com.\n \n \n Cautionary Statement Regarding Forward Looking Statements\n \n \n The statements in this press release that are not historical facts, and \n may constitute forward-looking statements that are based on curren...